Vytrus Biotech, S.A. (BME:VYT)

Vytrus Biotech Income Statement

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	6.09	4.7	4.48	3.51	2.23
Revenue Growth (YoY)	29.51%	4.90%	27.57%	57.47%	25.74%
Cost of Revenue	0.59	0.35	0.35	0.26	0.11
Gross Profit	5.5	4.35	4.13	3.25	2.12
Selling, General & Admin	3.76	3.29	2.86	2.29	1.57
Other Operating Expenses	-0.08	-0.07	-0.03	-0.02	-0.04
Operating Expenses	4.51	3.94	3.52	2.84	1.92
Operating Income	0.98	0.4	0.61	0.41	0.2
Interest Expense	-0.12	-0.15	-0.2	-0.12	-0.12
Interest & Investment Income	0.02	0.01	0.01	-	-
Currency Exchange Gain (Loss)	-0	-0.01	-0	-0	-0
Other Non Operating Income (Expenses)	0.03	0.03	0.03	0.02	-
EBT Excluding Unusual Items	0.91	0.29	0.44	0.31	0.08
Asset Writedown	-	-	-	-0	-0.03
Other Unusual Items	-0.01	0.02	0.01	0	-0
Pretax Income	0.9	0.31	0.45	0.31	0.09
Income Tax Expense	-0.12	-0.24	-0.15	-0.14	-0.13
Net Income	1.02	0.54	0.61	0.45	0.22
Net Income to Common	1.02	0.54	0.61	0.45	0.22
Net Income Growth	87.36%	-9.96%	34.49%	107.48%	-
Shares Outstanding (Basic)	8	7	-	7	7
Shares Outstanding (Diluted)	8	7	-	7	7
Shares Change (YoY)	11.71%	-	-	0.43%	-0.92%
EPS (Basic)	0.14	0.08	-	0.06	0.03
EPS (Diluted)	0.14	0.08	-	0.06	0.03
EPS Growth	67.72%	-	-	106.59%	-
Free Cash Flow	1.74	0.76	0.61	0.23	-0.32
Free Cash Flow Per Share	0.23	0.11	-	0.03	-0.05
Gross Margin	90.28%	92.46%	92.14%	92.60%	94.98%
Operating Margin	16.17%	8.60%	13.53%	11.65%	8.82%
Profit Margin	16.76%	11.59%	13.50%	12.81%	9.72%
Free Cash Flow Margin	28.62%	16.22%	13.51%	6.47%	-14.15%
EBITDA	1.18	0.6	0.75	0.99	0.59
EBITDA Margin	19.33%	12.67%	16.82%	28.06%	26.51%
D&A For EBITDA	0.19	0.19	0.15	0.58	0.39
EBIT	0.98	0.4	0.61	0.41	0.2
EBIT Margin	16.17%	8.60%	13.53%	11.65%	8.82%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.